Watchlist Price Alert

Carisma Therapeutics Inc. (CARM)

NASDAQ: CARM · Real-Time Price · USD

0.19

0.02 (14.18%)

At close: May 19, 2025, 3:59 PM

0.19

-0.05%

After-hours: May 19, 2025, 06:26 PM EDT

14.18% (1D)

Bid	0.19
Market Cap	7.95M
Revenue (ttm)	16.23M
Net Income (ttm)	-50.77M
EPS (ttm)	-1.22
PE Ratio (ttm)	-0.16
Forward PE	-0.28
Analyst	Hold

Ask	0.2
Volume	1,079,714
Avg. Volume (20D)	410,195
Open	0.17
Previous Close	0.17
Day's Range	0.16 - 0.19
52-Week Range	0.14 - 1.90
Beta	1.78

About CARM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CARM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CARM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Carisma Therapeutics has released their quartely earnings on May 13, 2025:

Revenue of $3.73M exceeds estimates by $1.26M, with 9.77% YoY growth.

EPS of -0.22 misses estimates by -0.12, with 52.17% YoY growth.

Why Price Moved

1 month ago

-25.65%

Carisma Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

5 months ago

-12.82%

Carisma Therapeutics shares are trading lower after Baird downgraded the stock from Outperform to Neutral and cut its price target from $10 to $1.

News

9 months ago · zacks.com

CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?

CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago · zacks.com

Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.

1 year ago · zacks.com

Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago.

1 year ago · zacks.com

Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago · zacks.com

Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now

CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among...

1 year ago · investorplace.com

3 Top Under-$5 Stocks for Strong Gains and Positive Outlook

To clearly set expectations from the get-go, these top stocks under $5 represent extraordinary risks. As either small or even micro-capitalization enterprises, you automatically should assume volatili...

1 year ago · zacks.com

Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know

The mean of analysts' price targets for Carisma Therapeutics Inc. (CARM) points to a 48.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

2 years ago · zacks.com

SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?

SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

2 years ago · 247wallst.com

Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio

Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN).